张晓晶：特聘研究员

职称职务：特聘研究员

学科专业：生物化学与分子生物学

研究方向：急、慢性肝脏损伤机制研究及药物开发

实验室位置：基础医学院3号楼612、614

Email： zhangxjing@whu.edu.cn

学习经历

2005.9~2009.7 北京中医药大学 药学院 制药工程 本科

2009.9~2012.7 北京大学医学部 药学院 天然药物化学 硕士

2012.8~2016.4 澳门大学 中华医院研究院 生物医药 博士

主要工作经历与任职

2016.7~2019.12 武汉大学人民医院 中心实验室 助理研究员

2020.1~2021.8 武汉大学 动物实验中心  特聘研究员

2021.9~至今  武汉大学 基础医学院  特聘研究员

目前主要科学研究领域和兴趣

非酒精性脂肪肝病相关肝脏代谢疾病病理机制及药物开发

缺血再灌注导致的多器官损伤核心驱动因素探索及药物开发

教学情况

《实验动物学》、《临床文献信息检索》

代表性论文（近5年，10篇以内的第一作者或通讯作者论文）

1) Cai J, Li H, Zhang C, Chen Z, Liu H, Lei F, Qin JJ, Liu YM, Zhou F, Song X, Zhou J, Zhao YC, Wu B, He M, Yang H, Zhu L, Zhang P, Ji YX, Zhao GN, Lu Z, Liu L, Mao W, Liao X, Lu H, Wang D, Xia X, Huang X, Wei X, Xia J, Zhang BH, Yuan Y, She ZG, Xu Q, Ma X, Wang Y*, Yang J*, Zhang X*, Zhang XJ*, Li H*. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. Cell Metab. 2021 Feb 2;33(2):258-269.e3.

2) Zhang L, She ZG, Li H*, Zhang XJ*. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clin Sci (Lond). 2020 Jul 17;134(13):1775-1799.

3) Jian C, Fu J, Cheng X, Shen LJ, Ji YX, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang HP, Zhang X, Wang Y, Huang Z, She ZG, Zhang XJ*, Zhu L*, Li H*. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metab. 2020 May 5;31(5):892-908.

4) Fang J, Ji YX, Zhang P, Cheng L, Chen Y, Chen J, Su Y, Cheng X, Zhang Y, Li T, Zhu X, Zhang XJ*, Wei X*. Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3. Hepatology. 2020 May;71(5):1592-1608.

5) Yan ZZ, Huang YP, Wang X, Wang HP, Ren F, Tian RF, Cheng X, Cai J, Zhang Y, Zhu XY, She ZG, Zhang XJ*, Huang Z*, Li H*. Integrated Omics Reveals Tollip as a Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice. Hepatology. 2019 Nov;70(5):1750-1769.

6) Zhang XJ#, Qin JJ#, Cheng X#, Shen L#, Zhao YC#, Yuan Y, Lei F, Chen MM, Yang H, Bai L, Song X, Lin L, Xia M, Zhou F, Zhou J, She ZG, Zhu L, Ma X, Xu Q, Ye P, Chen G, Liu L, Mao W, Yan Y, Xiao B, Lu Z, Peng G, Liu M, Yang J, Yang L, Zhang C, Lu H, Xia X, Wang D, Liao X, Wei X, Zhang BH, Zhang X, Yang J, Zhao GN, Zhang P, Liu PP, Loomba R, Ji YX, Xia J*, Wang Y*, Cai J*, Guo J*, Li H*. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.

7) Zhang XJ#, Cheng X#, Yan ZZ#, Fang J#, Wang X, Wang W, Liu ZY, Shen LJ, Zhang P, Wang PX, Liao R, Ji YX, Wang JY, Tian S, Zhu XY, Zhang Y, Tian RF, Wang L, Ma XL, Huang Z, She ZG, Li H*. An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med. 2018;24(1):73-83.

8) Zhang XJ, She ZG, Li H*. Time to step-up the fight against NAFLD. Hepatology. 2018 Jun;67(6):2068-2071.

9) Wang PX#, Ji YX#, Zhang XJ#, Zhao LP, Yan ZZ, Zhang P, Shen LJ, Yang X, Fang J, Tian S, Zhu XY, Gong J, Zhang X, Wei QF, Wang Y, Li J, Wan L, Xie Q, She ZG, Wang Z, Huang Z, Li H*. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med. 2017 Apr;23(4):439-449.

10) Yan FJ#, Zhang XJ#, Wang WX#, Ji YX, Wang PX, Yang Y, Gong J, Shen LJ, Zhu XY, Huang Z, Li H*. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis. Hepatology. 2017 May;65(5):1492-1511.